Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.Siontis KC1,2, Zhang X3 et al
based on this retrospective study it seems that non-reduced Apixaban dose should be used in ESKD